Intestinal Cell News Volume 10.10 | Mar 22 2024

    0
    7








    2024-03-22 | ICN 10.10


    Intestinal Cell News by STEMCELL Technologies
    Vol. 10.10 – 22 March, 2024
    TOP STORY

    Epidermal Growth Factor Receptor (EGFR) Is a Target of the Tumor-Suppressor E3 Ligase FBXW7

    Investigators used CRISPR base editors to introduce different F-box and WD repeat domain-containing 7 (FBXW7) hotspot mutations in human colon organoids.
    [Proceedings Of The National Academy Of Sciences Of The United States Of America]

    Full ArticlePress Release
    STEMCELL has implemented an Environmental Management System that is now ISO 14001-certified.
    PUBLICATIONSRanked by the impact factor of the journal

    Phenotypic Screen of 68 Colorectal Cancer Cell Lines Identifies CEACAM6 and CEACAM5 as Markers of Acid Resistance

    Scientists reported pH-related phenotypes of 68 colorectal cancer cell lines by measuring i) extracellular acidification as a readout of acid production by fermentative metabolism and ii) growth of cell biomass over a range of extracellular pH levels as a measure of the acid sensitivity of proliferation.
    [Proceedings Of The National Academy Of Sciences Of The United States Of America]

    Full Article

    Cancer-Derived Exosomal Alu RNA Promotes Colorectal Cancer Progression

    Researchers discovered that Alu RNA induced epithelial-to-mesenchymal transition through nucleotide-binding domain leucine-rich repeat containing 3 inflammasome activation and IL-1β release in colorectal cancer cells.
    [Experimental & Molecular Medicine]

    Full Article

    SIRT4 Loss Reprograms Intestinal Nucleotide Metabolism to Support Proliferation Following Perturbation of Homeostasis

    The authors investigated how mitochondrial sirtuin 4 (SIRT4) affected intestinal homeostasis. Intestinal SIRT4 loss promoted cell proliferation in the intestine following ionizing radiation.
    [Cell Reports]

    Full ArticleGraphical Abstract

    RNF166 Promotes Colorectal Cancer Progression by Recognizing and Destabilizing Poly-ADP-Ribosylated Angiomotins

    Investigators uncovered the involvement of an upregulated E3 ubiquitin ligase called RNF166, which destabilized angiomotins, activated yes-associated protein, and was associated with a poor prognosis in colorectal cancer patients.
    [Cell Death & Disease]

    Full Article

    Casein Kinase 2 Phosphorylates and Induces the SALL2 Tumor Suppressor Degradation in Colon Cancer Cells

    Scientists identified a novel casein kinase II-dependent mechanism for SALL2 regulation and provided new insights into the interplay between these two proteins and their role in cell survival and proliferation.
    [Cell Death & Disease]

    Full Article

    Notoginsenoside R1 Promotes Lgr5+ Stem Cell and Epithelium Renovation in Colitis Mice via Activating Wnt/β-Catenin Signaling

    Using a dextran sulfate sodium salt (DSS)-induced colitis mouse model, researchers investigated the reparative effects of notoginsenoside R1 on mucosal barrier damage after the acute injury stage of DSS exposure.
    [Acta Pharmacologica Sinica]

    Full ArticleGraphical Abstract
    Tips to prepare for your next conference or networking event
    REVIEWS

    Claudin 18.2 as a Novel Therapeutic Target

    Scientists highlight the biological rationale and explore the clinical activity of therapies that target claudin 18.2 in patients with advanced-stage gastric cancer and explore the potential for expansion of claudin 18.2-targeted therapies to patients with other claudin 18.2-positive solid tumours.
    [Nature Reviews Clinical Oncology]

    Abstract

    Role of Protein Degradation Systems in Colorectal Cancer

    The authors provide a comprehensive overview of the dual roles played by the ubiquitin‒proteasome system and autolysosome system in colorectal cancer, elucidating their impact on the initiation and progression of this disease while also highlighting their compensatory relationship.
    [Cell Death Discovery]

    Full Article
    INDUSTRY AND POLICY NEWS

    Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signateraâ„¢ in Stage II Colorectal Cancer

    Natera, Inc. announced a collaboration with the Fédération Francophone de Cancérologie Digestive and CHU Dijon Bourgogne on a prospective Phase III clinical trial in France investigating molecular residual disease guided adjuvant treatment in stage II colorectal cancer patients.
    [Natera, Inc.]

    Press Release
    FEATURED EVENT

    AI in Biomedicine

    May 1 – 3, 2024
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Scholar – Molecular Biology Research

    University of Kentucky – Lexington, Kentucky, United States

    PhD Student – Intestinal Tumorigenesis

    University of Montpellier – Montpellier, France

    Postdoctoral Scholar – Physiology

    The University of Tennessee Health Science Center – Memphis, Tennessee, United States

    PhD Position – Nanoparticles for Intestinal Diseases

    University of Groningen – Groningen, Netherlands

    Postdoctoral Fellow – Genetics and Epigenetics of Gastrointestinal Cancers

    City of Hope – Monrovia, California, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2